NCT05585931
Effect of TPN171H on Spermatogenesis
Evaluate the Acute Effects of a Single Oral Dose of TPN171H on Semen Function in Healthy Male Subjects in China
Vigonvita Life Sciences·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Erectile Dysfunction
- Drug/Device/Intervention
- TPN171H 10mg
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Vigonvita Life Sciences
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Nov 15, 2022
- End date
- Apr 01, 2023
- Enrollment
- 18 participants
Primary outcome
Effect on semen function,Seminal plasma exposure
Summary
This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in
 healthy male subjects.
ICD-10 classifications
Orgasmic dysfunctionOther disorders of penisOther specified disorders of penisSexual dysfunction, not caused by organic disorder or diseaseTesticular dysfunction
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05585931
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05585931 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.